Can Fite Biopharma Ltd (NASDAQ:CANF) has been assigned a $6.00 target price by equities researchers at HC Wainwright in a research note issued on Thursday. The brokerage currently has a “buy” rating on the stock.

Can Fite Biopharma (CANF) opened at 1.53 on Thursday. The stock has a 50 day moving average price of $1.77 and a 200 day moving average price of $1.86. Can Fite Biopharma has a 52-week low of $1.53 and a 52-week high of $2.82. The firm’s market cap is $23.72 million.

COPYRIGHT VIOLATION WARNING: This article was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/08/10/hc-wainwright-analysts-give-can-fite-biopharma-ltd-nasdaqcanf-a-6-00-price-target.html.

About Can Fite Biopharma

Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.

Receive News & Stock Ratings for Can Fite Biopharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma Ltd and related stocks with our FREE daily email newsletter.